西妥昔单抗联合其他治疗方法治疗头颈部鳞癌  

Cetuximab plus other methods in the treatment of patients with head and neck squamous cell carcinomas(HNSCC)

作　　者：许婷婷[1] 胡超苏[1] 应红梅[1] 朱国培[1] 吴永如[1] 

机构地区：[1]复旦大学附属肿瘤医院放疗科复旦大学上海医学院肿瘤学系,上海200032

出　　处：《中国癌症杂志》2008年第3期230-233,共4页China Oncology

摘　　要：背景与目的:头颈部鳞癌患者高表达表皮生长因子受体(epidermal growth factor receptor,EGFR)西妥昔单抗(cetuximab,C225,erbitux)作为一种抗EGFR的新型人鼠嵌合性单克隆抗体能有效抑制肿瘤细胞的生长。本研究观察西妥昔单抗联合其他治疗方法治疗晚期头颈部肿瘤的近期疗效、毒副反应。方法:20例头颈部鳞癌患者接受包括西妥昔单抗的综合治疗,C225每周一次给药,第一周400 mg/m2,以后每周250 mg/m2,联合治疗为以铂类为主的化疗以及适形或调强放射治疗,按RESIST标准评价疗效。结果:全组20例,CR 9例(45%),PR 10例(50%),SD 1例(5%),有效率(CR+PR)为95%。主要毒副反应为痤疮样皮疹。结论:西妥昔单抗联合治疗头颈部肿瘤安全有效,长期疗效有待进一步研究。Background and purpose： Epidermal growth factor receptor（EGFR） is highly expressed in head and neck squamous cell carcinoma patients. Cetuximab is a monoclonal antibody that blocks the EGFR and inhibits the tumor cell. This study assessed the efficiency and side effects of cetuximab in head and neck cancer. Methods： 20 patients with head and neck squamous cell carcinoma（HNSCC） received comprehensive therapy including cetuximab. C225 was administered once each week, 400 mg/m2 first dose and 250 mg/m2 the following dose. Chemotherapy included platinum and 3D-CRT/ IMRT was employed for radiotherapy. Results： In the 20 cases there were 9 patients CR（45% ） , 10 patients PR（50%）, 1 patient SD（ 5% ）. The immediate response rate was 95%. The main side effect was acne-like rash. Conclusions： Cetuximab combined with chemoradiotherapy is effective to HNSCC and more studies are needed to prove its long-dated effects.

关 键 词：西妥昔单抗 头颈部鳞癌 化疗 

分 类 号：R730.53[医药卫生—肿瘤] R739.91[医药卫生—临床医学]